Possible association between adult T-cell leukemia/lymphoma and acute myeloid leukemia

被引:1
作者
Tsukasaki, K [1 ]
Koba, T [1 ]
Iwanaga, M [1 ]
Murata, K [1 ]
Maeda, T [1 ]
Atogami, S [1 ]
Nakamura, H [1 ]
Yamada, Y [1 ]
Kamihira, S [1 ]
Tomonaga, M [1 ]
机构
[1] Nagasaki Univ, Dept Hematol, Inst Atom Dis, Nagasaki 852, Japan
关键词
adult T-cell leukemia/lymphoma; acute myeloid leukemia; cytokine; chemotherapy; superimposing;
D O I
10.1002/(SICI)1097-0142(19980201)82:3<488::AID-CNCR10>3.0.CO;2-Y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. To the authors' knowledge, an association between adult T-cell leukemia/lymphoma (ATL) and acute myeloid leukemia (AML) has been reported only in four patients. The authors identified five additional patients with both neoplasms. METHODS. A review of the clinical records of patients with AML, ATL, or lymphoid neoplasms other than ATL diagnosed between 1986 and 1995 was performed. Cytokine levels were assayed in selected patients. The authors searched for reports from other institutions using MEDLINE and the proceedings of two Japanese hematology societies. RESULTS. ATL was diagnosed in 134 patients, whereas 180 had AML. Five patients with both neoplasms were identified (3.7% of ATL patients and 2.8% of AML patients). In seven of the nine patients (including four patients in the literature) with ATL and AML, the ATL was diagnosed prior to the AML, whereas in the remaining two patients both neoplasms were diagnosed simultaneously. Six of the nine cases were therapy-related (t)-AML, which developed after chemotherapy for ATL. Monoclonal integration of proviral human T-lymphotropic virus type 1 was detected in ATL cells but not in AML cells in the six patients examined. The plasma levels of macrophage colony-stimulating factor (M-CSF), granulocyte-colony stimulating factor, and granulocyte-macrophage-colony stimulating factor (GM-CSF) were elevated in 3, 1, and 1, respectively, of the 4 patients examined at AML onset who had active ATL. In one case, the levels of several cytokines, including GM-CSF and M-CSF, in the supernatant fluid of short term cultured ATL cells were elevated. Three patients with de novo ATL and AML received remission induction therapy, and two achieved a complete remission (CR) of both diseases. Among the four patients who received chemotherapy for t-AML, two achieved CR. CONCLUSIONS. ATL patients also can develop AML, irrespective of treatment with chemotherapy for ATL. This association does not indicate exclusive chemoresistance of both neoplasms. Cytokines produced by ATL cells may support the growth of AML cells. (C) 1998 American Cancer Society.
引用
收藏
页码:488 / 494
页数:7
相关论文
共 38 条
[1]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[2]  
CHEN YC, 1989, BLOOD, V74, P388
[3]   2ND MALIGNANCIES IN PATIENTS WHO HAVE HEAD AND NECK-CANCER - INCIDENCE, EFFECT ON SURVIVAL AND IMPLICATIONS BASED ON THE RTOG EXPERIENCE [J].
COOPER, JS ;
PAJAK, TF ;
RUBIN, P ;
TUPCHONG, L ;
BRADY, LW ;
LEIBEL, SA ;
LARAMORE, GE ;
MARCIAL, VA ;
DAVIS, LW ;
COX, JD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (03) :449-456
[4]  
JACOBS RH, 1985, CANCER-AM CANCER SOC, V56, P1462, DOI 10.1002/1097-0142(19850915)56:6<1462::AID-CNCR2820560639>3.0.CO
[5]  
2-6
[6]  
Kozuru M, 1996, CANCER, V78, P1119, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1119::AID-CNCR24>3.0.CO
[7]  
2-4
[8]   A CELL INITIATING HUMAN ACUTE MYELOID-LEUKEMIA AFTER TRANSPLANTATION INTO SCID MICE [J].
LAPIDOT, T ;
SIRARD, C ;
VORMOOR, J ;
MURDOCH, B ;
HOANG, T ;
CACERESCORTES, J ;
MINDEN, M ;
PATERSON, B ;
CALIGIURI, MA ;
DICK, JE .
NATURE, 1994, 367 (6464) :645-648
[9]  
LEVINE EG, 1992, SEMIN ONCOL, V19, P47
[10]   MULTIPLE PRIMARY-CANCER IN PATIENTS WITH CANCER OF THE HEAD AND NECK - 2ND CANCER OF THE HEAD AND NECK, ESOPHAGUS, AND LUNG [J].
LICCIARDELLO, JTW ;
SPITZ, MR ;
HONG, WK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (03) :467-476